2010-Present Publications

2010-Present Publications

 

1. “Photosensitizer–antibiotic conjugates: A novel class of antibacterial molecules”, Cahan R., Swissa N., Gellerman G., Nitzan Y., Photochemistry and Photobiology, 2010, 86(2), 418-425.

2. “One-pot derivatization of medicinally important 9-aminoacridine by reductive amination and SNAr” Gellerman G., Gaisin N., Brider T. Tetrahedron Lett., 51,836–839, 2010.

3. “Phenols – useful templates for the synthesis of bi-functional orthogonally protected dendron building blocks via Solid Phase Mitsunobu reaction”, Gellerman G., Shitrit S., Shalit T., Ganot O., Albeck A., Tetrahedron, 66, 878–886, 2010

4.“A double heteroatom Mitsunobu coupling with amino hydroxybenzoic acids on solid phase: a novel aspect of Mitsunobu reaction to form dendron building blocks.” Shalit T., Albeck A., Gellerman G., Tetrahedron Lett., 51, 5988–5991, 2010.

5. “One-Pot Synthesis of Novel Antiproliferative 9-Aminoacridines”. Gellerman G., Waintraub S., Gaisin V., Jour. Org. Chem., 22, 4176–4182, 2011.

6. “A fast entry to the novel medicinally important 9-anilinoacridine peptidyls by solid phase organic synthesis (SPOS)”, Brider T., Gilad Y., Gellerman G., Tetrahedron Lett.,52, 3640-44, 2011.
<

7. “Recent Synthetic Approaches to anticancer 9-anilinoacridines. A Review“, Gellerman G., Prep. Proced. Inter., 44, 187–221, 2012.

8.“A two-step synthesis of medicinally-important 1,8-naphthalimide peptidyls by solid phase organic synthesis (SPOS)” Brider T., Gellerman G., Tetrahedron Lett., 53, 5611–5615, 2012.

9.“Facile synthesis of potential antitumor novel N(9) methylated AHMA analogs”, Redko B., Albeck A., Gellerman G., New Jour. Chem., 36, 2188–2191, 2012.

10.“Targeted drug delivery for cancer therapy: the other side of antibodies” Firer M. A., Gellerman G., Hematol. Oncol., 5:70, 1-16, 2012.

11.“MBP-chlorambucil conjugates: Improving the efficacy of targeted drug delivery to murine models of Multiple Myeloma (MM) cells”, Gellerman G., Baskin S., Gilad Y., Firer M. A., Anti-Cancer Drugs, 24, 112-119,

12.“Penta-glycine-Ni(II) Complex: From Kinetics to Structure”, Gaisin Z., Gellerman G., Meyerstein D., Jour. Inorg. Chem., 3191–3194, 2013.

13.“Switch off/switch on” regulation of drug cytotoxicity by conjugation to a cell targeting peptide” Gilad Y., Firer M. A., Rozovsky A., Ragozin E., Redko B., Albeck A., Gellerman G., Jour. Med. Chem., 85, 139-146, 2014.

14.”Three overlooked chemical approaches toward 3-naphtalimide amonafide N-derivatives” Brider T., Grynszpan F., Gellerman G., Lett., 55, 6675-6679, 2014.

15.“Anti-proliferative activity of the combination of salan Ti(IV) complexes with other organic and inorganic anticancer drugs against HT-29 and NCIH1229 cells: synergism with cisplatin” Ganot N., Redko B., Gellerman G., Tshuva E. Y., RSC Adv., 5, 7874–7879, 2015.

16. “Synthesis of novel antitumor carbazole-amonafide structural hybrids” Rozovsky A., Regozin E., Oron-Herman M., Albeck A., Gellerman G., J. Org. Chem, 1811–1818, 2015.

17. “Antiproliferative Effects of Novel Aminoacridine-Based Compounds” Munder A., Moskovitz Y., Redko B., Levy A. R., Ruthstein S., Gellerman G., Gruzman A. Chem., 11, 373-38, 2015.

18. ”1,4-Dihydropyridine Cationic Peptidomimetics with Antibacterial Activity” Lapidot I., Albeck A., Gellerman G., Shatzmiller S., Grynszpan F. Int. J. Pept. Res. Ther. 2015, 21, 243-247.

19. “a-Aminoisobutyric acid leads a fluorescent syn-bimane LASER probe across the blood-brain barrier”, I. Lapidot, D. Baranes, A. Pinhasov, Gellerman G., A. Albeck, F. Grynszpan, Shatzmiller, Med. Chem., 2015, DOI: 10.2174/1573406411666150518105010

20. “Synthesis, drug release and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety” Redko, B., Ragozin, E., Bazylevich, A., Tuchinsky, H., Albeck, A., Shekhter Zahavi, T., Oron-Herman, M., Kostenich, G., Gellerman, G*. Science (Biopolymers), 104(6), 743–752, 2015.

21. “Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery” Gilad Y., Noy E., Senderowitz H., Albeck A., Firer M. A., Gellerman G.* Bioorganic & Medicinal Chemistry, 2016, 294–

22. “Bio-Labile Peptidyl Delivery Systems Towards Sequential Drug Release” Ragozin E., Redko B., Tuchinsky E., Rozovsky A., Amnon A., Grynszpan F., Gellerman G.*, Peptide Science (Biopolymers), 2015, (116), 119-132.

23. “Recent Developments in the Synthesis and Applications of Anticancer Amonafide Derivatives. A Mini Review”, Gellerman G.* Drug Des. Discov., 2016, 13(1): 47 – 63.

24. “Synthesis of novel protected Nα(ω-Drug) amino acid building units for facile preparation of anticancer drug-conjugates” Gilad Y., Waintraub S., Albeck A. Gellerman G.* J. Pept. Res. Ther. 2016, DOI 10.1007/s10989-015-9509-1.

25. “Synthesis and in-vitro anticancer evaluation of 1,8-naphthalimide N(4) and S(4)-derivatives combining DNA intercalation and alkylation capabilities”, T. Brider, B. Redko, M. Oron-Herman, A. Cohen-Matzlich, G. Gerlitz, Gellerman G.,* F. Grynszpan,* Chem. Intermed. (2016), 42:1741–1757.

26. “Dual-drug RGD conjugates provide enhanced cytotoxicity of melanoma and non-small lung cancer cells”, Gilad Y., Noy E., Senderowitz H., Albeck A., Firer M. A., Gellerman G.*, Peptide Science (Biopolymers), 2016, 106(2), 160-171.

27. ”Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells”, Gilad Y., Firer M., Gellerman G., Biomedicines 2016, 4, 11.

28. “Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma” Redko B., Tuchinsky L., Segal T., Tobi D., Luboshits G., Ashur-Fabian O., Pinhasov A., Gerlitz G., Gellerman G., Oncotarget, 2016, Oncotarget, 2017(8)

29. ‘’Exploiting Fluorescein Based Drug Conjugates for Fluorescent Monitoring in Drug Delivery’’ Bazylevich, L. D. Patsenker G. Gellerman, Dyes and Pigments 2016, 2017, 139, 460-472.

  1. ”Discovery of potent molecular chimera (CM358) to treat human metastatic melanomaGilad Y., Tuchinsky H., Firer M., Gellerman G., Eur. J. Med Chem. 138 (2017) 602-615